RxDoctor Payments DataLook up a doctor →

Bradley McClure, MD

Psychiatry · Tulsa, OKNPI 1790755916

Payments from drug & device makers

$15,061in general payments, 2019–2025

Across 945 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$2K
  • Alkermes, Inc.$1K
  • Corium, LLC$1K
  • Lundbeck LLC$1K
  • Vanda Pharmaceuticals Inc.$955
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$14,94299%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,061 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.

See all psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$21,233
Medicare patients
77
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine22$155,699
VraylarCariprazine Hcl84$132,692
Invega SustennaPaliperidone Palmitate15$57,714
RexultiBrexpiprazole29$48,595
Aripiprazole351$16,770
TrintellixVortioxetine Hydrobromide30$14,136
Vilazodone Hcl91$9,441
Duloxetine Hcl268$9,106
VyvanseLisdexamfetamine Dimesylate20$7,825
ViibrydVilazodone Hcl20$7,162
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine161$6,717
Buspirone Hcl421$6,371
Desvenlafaxine Succinate ErDesvenlafaxine Succinate107$6,162
Bupropion XlBupropion Hcl240$4,747
Trazodone Hcl234$4,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$680$155,69922 claims
AbbVieVraylar, Viibryd$2,069$139,854104 claims
Johnson & JohnsonInvega Sustenna, Concerta$616$61,92128 claims
Otsuka America Pharmaceutical, Inc.Rexulti$2,136$48,59529 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$955$21,96150 claims
Almatica Pharma LLCSertraline Hcl$150$1,312116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.

Other psychiatry in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →